N/A
N=30
Multiplexing Prism Fitting for Field Expansion of Monocular Vision
One Eye Blindness · Blind Left Eye · Blind Right Eye
Bottom Line
View on ClinicalTrials.gov: NCT06027216 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Gain in Visual Field With the Multiplexing Prism — 24 degrees
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Multiplexing Prism (Device)
- Age
- Pediatric, Adult, Older Adult · 16+ yrs
- Sex
- All
- Sponsor
- Massachusetts Eye and Ear Infirmary
- Primary completion
- Oct 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Gain in Visual Field With the Multiplexing Prism |
24 | — |
| SECONDARY Maximum Extent of Nasal Visual Field With the Multiplexing Prism |
79 | — |
Summary
The investigators are developing an assistive device, known as multiplexing prism that expands the field of view for individuals with acquired monocular vision (loss of an eye). The investigators are testing a simplified design and fitting protocol to provide field expansion for individuals with acquired monocular vision.
Eligibility Criteria
Inclusion Criteria
- No medical health issues such as seizures, motor movements problem
- Loss of vision in one eye (less than 20/200) for >1 year)
- Visual acuity of the seeing eye: Better than 20/32 visual acuity with correction
- No visual field defect in the seeing eye (nasal field of at least >45degree)
- No medical health issues such as seizures, motor movements problem
Exclusion Criteria
- Patients with any physical or mental disabilities, including cognitive dysfunction, balance problems, or other deficits that could impair their ability to respond to the stimuli presented in this study will be excluded
- Any person with motor movements problem (e.g., unable to use extremities)
Data sourced from ClinicalTrials.gov (NCT06027216). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.